When the FDA approves existing drugs for new uses, it can disrupt the marketplace – and companies need to know how to adapt to the new sales environment.
Glucagon-like peptide-1 (GLP-1) drugs are disrupting the MedTech marketplace right now. Previously used to treat type 2 diabetes, these drugs are the latest weapon in the battle against obesity, and they are so effective that the number of bariatric surgeries is declining. But will GLP-1s continue to be the treatment of choice, permanently reducing the number of bariatric surgeries, or will the trend decline because of high costs not covered by insurance?
When markets are so unpredictable, sales operations must adapt to fairly compensate sales reps. This white paper shows how to adjust incentive compensation plans to reward your sales team fairly.